Form 4: United Therapeutics COO Sells $9.9M in Shares

United Therapeutics' President and COO, Michael Benkowitz, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 22,500 shares for approximately $9.9 million.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in stock option exercises and subsequent share sales on October 13, 2025.
• He exercised options to acquire 14,625 shares of common stock at an exercise price of $135.42 per share.
• These 14,625 shares were then sold at a price of $440.3539 per share.
• Additionally, he exercised options for 7,875 shares of common stock at an exercise price of $146.03 per share.
• These 7,875 shares were also sold at $440.3539 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• The shares involved were held indirectly through trusts where Mr. Benkowitz is a beneficiary and holds investment and voting power.

Sentiment

Score: 6

Explanation: The filing reports a pre-planned insider transaction (exercise of options and sale of shares) under a Rule 10b5-1 plan. While the sale of shares by an executive can sometimes be viewed negatively, the pre-arranged nature mitigates concerns about opportunistic selling. The high sale price reflects a strong valuation for the company's stock.

Positives

• The high sale price of $440.3539 per share indicates a significant profit for the insider, reflecting a strong market valuation for United Therapeutics' stock.
• The transactions were executed under a Rule 10b5-1 trading plan, which demonstrates pre-planned and transparent activity, mitigating concerns about opportunistic insider trading.

Negatives

• Insider selling, even when pre-arranged, can sometimes be perceived by the market as a signal of an executive's reduced confidence in the company's future stock price appreciation.
• The sale of 22,500 shares represents a substantial liquidation of personal holdings by a key executive.

Future Outlook

NA

Management Comments

• The exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.

Industry Context

NA

Related Party Transactions

• Transactions involved shares held in a trust beneficially owned by the Reporting Person, where he and his spouse are co-trustees with shared investment and voting power.
• Additional transactions involved shares held in a trust beneficially owned by the Reporting Person's family members, where the Reporting Person has sole investment and voting power.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some might see it as profit-taking, others as a potential signal. The pre-planned nature under 10b5-1 generally reduces negative interpretations.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is mentioned in this filing.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a key executive. While the executive is realizing significant gains, which is positive for the individual, it does not provide new fundamental information about the company's operations or future prospects. The 10b5-1 plan indicates a scheduled transaction rather than a reaction to new, undisclosed information. Therefore, without additional company-specific news, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or strategic updates.

Keywords

UTHR, United Therapeutics, Michael Benkowitz, insider trading, stock options, 10b5-1 plan, beneficial ownership, SEC Form 4, officer transaction